These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 33279180)

  • 1. CD33 directed bispecific antibodies in acute myeloid leukemia.
    Clark MC; Stein A
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101224. PubMed ID: 33279180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD123 bi-specific antibodies in development in AML: What do we know so far?
    Slade MJ; Uy GL
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101219. PubMed ID: 33279175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigational CD33-targeted therapeutics for acute myeloid leukemia.
    Walter RB
    Expert Opin Investig Drugs; 2018 Apr; 27(4):339-348. PubMed ID: 29534618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.
    Hoseini SS; Vadlamudi M; Espinosa-Cotton M; Tran H; Feng Y; Guo HF; Xu H; Cheung I; Cheung NV
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia.
    Venugopal S; Daver N; Ravandi F
    Curr Hematol Malig Rep; 2021 Feb; 16(1):89-96. PubMed ID: 33630233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
    Reusing SB; Vallera DA; Manser AR; Vatrin T; Bhatia S; Felices M; Miller JS; Uhrberg M; Babor F
    Cancer Immunol Immunother; 2021 Dec; 70(12):3701-3708. PubMed ID: 34398302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.
    Reusch U; Harrington KH; Gudgeon CJ; Fucek I; Ellwanger K; Weichel M; Knackmuss SH; Zhukovsky EA; Fox JA; Kunkel LA; Guenot J; Walter RB
    Clin Cancer Res; 2016 Dec; 22(23):5829-5838. PubMed ID: 27189165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells.
    Yan Z; Gu R; Ma H; Chen N; Zhang T; Xu Y; Qiu S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Cell Oncol (Dordr); 2024 Oct; 47(5):1879-1895. PubMed ID: 39008193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
    Han YC; Kahler J; Piché-Nicholas N; Hu W; Thibault S; Jiang F; Leal M; Katragadda M; Maderna A; Dushin R; Prashad N; Charati MB; Clark T; Tumey LN; Tan X; Giannakou A; Rosfjord E; Gerber HP; Tchistiakova L; Loganzo F; O'Donnell CJ; Sapra P
    Clin Cancer Res; 2021 Jan; 27(2):622-631. PubMed ID: 33148666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.
    Leong SR; Sukumaran S; Hristopoulos M; Totpal K; Stainton S; Lu E; Wong A; Tam L; Newman R; Vuillemenot BR; Ellerman D; Gu C; Mathieu M; Dennis MS; Nguyen A; Zheng B; Zhang C; Lee G; Chu YW; Prell RA; Lin K; Laing ST; Polson AG
    Blood; 2017 Feb; 129(5):609-618. PubMed ID: 27908880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.
    Friedrich M; Henn A; Raum T; Bajtus M; Matthes K; Hendrich L; Wahl J; Hoffmann P; Kischel R; Kvesic M; Slootstra JW; Baeuerle PA; Kufer P; Rattel B
    Mol Cancer Ther; 2014 Jun; 13(6):1549-57. PubMed ID: 24674885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of CD33 as therapeutic target in acute myeloid leukemia.
    Walter RB
    Expert Opin Ther Targets; 2014 Jul; 18(7):715-8. PubMed ID: 24750020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia.
    Walter RB
    Expert Rev Hematol; 2014 Jun; 7(3):317-9. PubMed ID: 24617311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The past and future of CD33 as therapeutic target in acute myeloid leukemia.
    Laszlo GS; Estey EH; Walter RB
    Blood Rev; 2014 Jul; 28(4):143-53. PubMed ID: 24809231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy.
    Godwin CD; Laszlo GS; Fiorenza S; Garling EE; Phi TD; Bates OM; Correnti CE; Hoffstrom BG; Lunn MC; Humbert O; Kiem HP; Turtle CJ; Walter RB
    Leukemia; 2021 Sep; 35(9):2496-2507. PubMed ID: 33589747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.
    Aigner M; Feulner J; Schaffer S; Kischel R; Kufer P; Schneider K; Henn A; Rattel B; Friedrich M; Baeuerle PA; Mackensen A; Krause SW
    Leukemia; 2013 Apr; 27(5):1107-15. PubMed ID: 23178753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
    Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
    Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential role of Bi-specific antibodies in acute myeloid leukemia.
    Yilmaz M; Ravandi F
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101218. PubMed ID: 33279174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute myeloid leukemia targets for bispecific antibodies.
    Hoseini SS; Cheung NK
    Blood Cancer J; 2017 Feb; 7(2):e522. PubMed ID: 28157217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors.
    Assi R; Kantarjian H; Ravandi F; Daver N
    Curr Opin Hematol; 2018 Mar; 25(2):136-145. PubMed ID: 29206680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.